You have 9 free searches left this month | for more free features.

ribociclib

Showing 1 - 25 of 78

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Breast Cancer Trial in Ann Arbor (Ribociclib, Postoperative Radiation Therapy)

Not yet recruiting
  • Breast Cancer
  • Ribociclib
  • Postoperative Radiation Therapy
  • Ann Arbor, Michigan
    University of Michigan
Aug 10, 2023

Early Breast Cancer Trial (Ribociclib, Letrozole, Ansastrozole)

Not yet recruiting
  • Early Breast Cancer
  • Ribociclib
  • +4 more
  • (no location specified)
Apr 12, 2023

Breast Cancer Trial ([68Ga]Ga-NeoB, [177Lu]Lu-NeoB, Ribociclib)

Not yet recruiting
  • Breast Cancer
  • (no location specified)
May 22, 2023

Ribociclib in Combination With Non-steroidal Aromatase

Completed
  • Breast Cancer
  • Ribociclib
  • Sao Paulo, SP, Brazil
    Novartis Investigative Site
Nov 7, 2022

Breast Cancer Trial in Boston, Danvers (Ribociclib, Endocrine therapy)

Recruiting
  • Breast Cancer
  • Ribociclib
  • Endocrine therapy
  • Boston, Massachusetts
  • +2 more
Jan 6, 2023

Glioblastoma Multiforme, Glioma of Brain Trial in Chandler, Phoenix, Scottsdale (Ribociclib, Everolimus)

Completed
  • Glioblastoma Multiforme
  • Glioma of Brain
  • Chandler, Arizona
  • +2 more
Jan 11, 2023

Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Prostate Carcinoma Metastatic in the Bone Trial in United

Recruiting
  • Hormone-Resistant Prostate Cancer
  • +3 more
  • Ann Arbor, Michigan
  • +3 more
Feb 2, 2023

Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Carcinoma Trial in United States (ribociclib, Paclitaxel, Carboplatin)

Completed
  • Ovarian Cancer
  • +2 more
  • ribociclib
  • +2 more
  • Ann Arbor, Michigan
  • +7 more
Sep 1, 2022

Triple Negative Breast Cancer Trial in United States (ribociclib, Bicalutamide)

Recruiting
  • Triple Negative Breast Cancer
  • Chicago, Illinois
  • +5 more
Oct 31, 2022

Locoregional Recurrence, Hormone Receptor-positive Breast Cancer, HER2-negative Breast Cancer Trial (Ribociclib, Fulvestrant,

Not yet recruiting
  • Locoregional Recurrence
  • +2 more
  • Ribociclib
  • +4 more
  • (no location specified)
Jul 18, 2022

Breast Cancer Trial in Prato (Ribociclib, Aromatase Inhibitors, non steroideal, LHRH agonist)

Recruiting
  • Breast Cancer
  • Ribociclib
  • +2 more
  • Prato, Please Select:, Italy
    Hospital of Prato
Jul 27, 2022

Head and Neck Squamous Cell Carcinoma Trial in Taipei (Ribociclib, Spartalizumab)

Active, not recruiting
  • Head and Neck Squamous Cell Carcinoma
  • Taipei, Taiwan
    National Taiwan University Hospital
Apr 19, 2022

Neuroblastoma Trial (Topotecan, Temozolomide, Ribociclib)

Not yet recruiting
  • Neuroblastoma
  • (no location specified)
Jun 17, 2022

Breast Cancer Stage IV Trial in Nice, Villejuif (Alpelisib, Ribociclib)

Not yet recruiting
  • Breast Cancer Stage IV
  • Nice, France
  • +1 more
Nov 14, 2022

Prostate Cancer Trial in United States (Docetaxel-PNP, Ribociclib, Prednisone)

Completed
  • Prostate Cancer
  • San Francisco, California
  • +5 more
Aug 9, 2022

Diffuse Intrinsic Pontine Glioma, Malignant Glioma of Brain, High Grade Glioma Trial in United States (ribociclib, Everolimus)

Completed
  • Diffuse Intrinsic Pontine Glioma
  • +6 more
  • Washington, District of Columbia
  • +6 more
Jan 12, 2023

Lymphoma, Solid Tumor Trial in Buffalo (Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study)

Terminated
  • Lymphoma
  • Solid Neoplasm
  • Gemcitabine Hydrochloride
  • +3 more
  • Buffalo, New York
    Roswell Park Cancer Institute
Jul 20, 2022

Metastatic Breast Cancer, Recurrent Ovarian Carcinoma Trial in Salt Lake City, Fairfax (Ribociclib, Belinostat)

Recruiting
  • Metastatic Breast Cancer
  • Recurrent Ovarian Carcinoma
  • Salt Lake City, Utah
  • +1 more
May 3, 2022

Breast Cancer Trial in Washington, Baltimore, Boston (Ribociclib)

Recruiting
  • Breast Cancer
  • Ribociclib
  • Washington, District of Columbia
  • +3 more
Feb 15, 2022

Metastatic Breast Cancer, Advanced Breast Cancer, HR-positive Breast Cancer Trial (OP-1250, Ribociclib, Alpelisib)

Not yet recruiting
  • Metastatic Breast Cancer
  • +3 more
  • (no location specified)
Aug 18, 2022

Metastatic Hormone-Receptor-Positive (HR+) Breast Cancer, HER2-Negative Breast Cancer, Metastatic Epithelial Ovarian Cancer

Terminated
  • Metastatic Hormone-Receptor-Positive (HR+) Breast Cancer
  • +2 more
  • Ribociclib
  • +2 more
  • Boston, Massachusetts
  • +2 more
Mar 16, 2022

Breast Cancer Metastatic Trial in Ravensburg (Ribociclib, Anastrozole, Letrozole)

Active, not recruiting
  • Breast Cancer Metastatic
  • Ribociclib
  • +4 more
  • Ravensburg, Germany
    Studienzentrum Onkologie Ravensburg
Mar 7, 2022

Recurrent Endometrial Carcinoma, Recurrent Endometrial Endometrioid Adenocarcinoma, Refractory Endometrial Carcinoma Trial in

Recruiting
  • Recurrent Endometrial Carcinoma
  • +12 more
  • Houston, Texas
  • +1 more
Sep 22, 2022

Breast Cancer, Breast Cancer - Female, Breast Cancer - Male Trial in Tampa (Tamoxifen, Ribociclib, Goserelin)

Completed
  • Breast Cancer
  • +2 more
  • Tampa, Florida
    H. Lee Moffitt Cancer Center and Research Institute
Jan 13, 2022